FDA Framework for AI/ML-Enabled Medical Devices: Predetermined Change Control Plans

FDA Framework for AI/ML-Enabled Medical Devices: Predetermined Change Control Plans

The FDA’s approach to regulating AI/ML-enabled medical devices centers on a “total product lifecycle” framework and the concept of Predetermined Change Control Plans (PCCPs), allowing approved devices to evolve after market authorization without requiring new submissions for every update.

The Framework

The U.S. Food and Drug Administration regulates AI/ML-enabled software that meets the definition of a medical device under the Federal Food, Drug, and Cosmetic Act. As of 2025, the FDA has cleared or authorized more than 950 AI/ML-enabled medical devices through the 510(k), De Novo, and PMA pathways.

The agency’s regulatory framework is built around several key guidance documents and concepts:

Predetermined Change Control Plans (PCCPs)

A PCCP allows a manufacturer to describe in their initial submission what types of modifications they plan to make to the AI/ML algorithm after deployment — such as retraining with new data or adjusting model parameters. If the FDA approves the PCCP, the manufacturer can implement those specific changes without filing a new submission for each update.

This is a significant departure from the traditional medical device model, where any modification requires a new 510(k) or supplement. The FDA recognized that AI/ML algorithms are inherently iterative — they learn and adapt — and a traditional regulatory framework would stifle clinically beneficial improvements.

Good Machine Learning Practice (GMLP)

The FDA, in collaboration with Health Canada and the UK’s MHRA, published a set of Good Machine Learning Practice guiding principles in October 2021. These 10 principles cover:

  • Applying software engineering and quality system practices throughout the product lifecycle
  • Clinically robust training and testing datasets that reflect the intended patient population
  • Independent review of training data by qualified experts
  • Device performance monitoring and iterative improvement

Transparency and Bias

The FDA has emphasized the importance of transparency in AI/ML devices, particularly regarding:

  • How the device’s inputs and outputs should be interpreted
  • Limitations and contraindications
  • Populations for which the device has been tested and validated
  • Potential for bias if the training data does not represent the intended use population

Relationship to EU AI Act

Under the EU AI Act, most AI-enabled medical devices are classified as “high-risk” AI systems and are subject to conformity assessment requirements before being placed on the EU market. This includes risk management systems, data governance, technical documentation, and human oversight requirements. The FDA framework, by contrast, operates through device-specific clearance pathways rather than a horizontal AI-specific regulation.

Primary Sources


AI automated and generated content. Human reviewed. All policy text is summarized from the primary sources linked above.

The Weekly AI Policy Brief

AI policy moves fast. Get the week’s developments, new trackers, and podcast episodes in one short email — free, ad-free, no spam.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *